Platelet-Leukocyte Aggregate and Interleukin-6: An Emerging Perspective on a New Diagnostic and Therapeutic Clue for Acute Coronary Syndrome, A Case-Control Study.

Background And Aims: Acute coronary syndrome (ACS) is one of the most important cardiovascular diseases. The rupture of atherosclerotic plaques in coronary arteries is considered the underlying pathophysiology of ACS. The interaction between cytokines and leukocytes in the presence of platelets results in platelet-leukocyte aggregate (PLA).

Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective.

Non-Hodgkin lymphomas (NHLs) are heterogeneous and are among the most common hematological malignancies worldwide. Despite the advances in the treatment of patients with NHLs, relapse or resistance to treatment is anticipated in several patients. Therefore, novel therapeutic approaches are needed.

Royal jelly induces ROS-mediated apoptosis in acute lymphoblastic leukemia (ALL)-derived Nalm-6 cells: Shedding light on novel therapeutic approaches for ALL.

Objectives: Until recently, a conventional chemotherapy regimen for Acute lymphoblastic leukemia (ALL) is considered an efficient therapeutic method in children. However, suboptimal long-term survival rates in adults, disease relapse, and drug-induced toxicities require novel therapeutic agents for ALL treatments. Today, natural products with pharmacological benefits play a significant role in treating different cancers.

Cytokine-Induced Memory-Like NK Cells: Emerging strategy for AML immunotherapy.

Acute myeloid leukemia (AML) is a heterogeneous disease developed from the malignant expansion of myeloid precursor cells in the bone marrow and peripheral blood. The implementation of intensive chemotherapy and hematopoietic stem cell transplantation (HSCT) has improved outcomes associated with AML, but relapse, along with suboptimal outcomes, is still a common scenario. In the past few years, exploring new therapeutic strategies to optimize treatment outcomes has occurred rapidly.

Microfluidic Droplet-Generation Device with Flexible Walls.

Controlling droplet sizes is one of the most important aspects of droplet generators used in biomedical research, drug discovery, high-throughput screening, and emulsion manufacturing applications. This is usually achieved by using multiple devices that are restricted in their range of generated droplet sizes. In this paper, a co-flow microfluidic droplet-generation device with flexible walls was developed such that the width of the continuous (C)-phase channel around the dispersed (D)-phase droplet-generating needle can be adjusted on demand.